NeuroThera Labs Inc., a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced that its collaboration with Clearmind Medicine Inc. has resulted in a patent application filed in Hong Kong for an innovative combination therapy designed to treat major depressive disorder. The therapy combines Clearmind's proprietary compound 5-methoxy-2-aminoindane with Palmitoylethanolamide sourced by NeuroThera.
The patent filing highlights the potential of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally according to World Health Organization data. Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors and other conventional options.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on discovering and developing novel psychedelic-derived therapeutics to solve widespread health problems. The company's intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND." For further information, visit https://www.clearmindmedicine.com.
The announcement contains forward-looking statements regarding the potential therapeutic benefits of the MEAI-PEA combination therapy, its potential advantages over existing antidepressants, and the presumed mechanism of action as a non-hallucinogenic neuroplastogen. These statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results to differ materially from projections.
Risks and uncertainties include the early stage of development of the MEAI-PEA combination, the inherent uncertainty of preclinical and clinical outcomes, and the risk that the combination therapy may not demonstrate anticipated safety, efficacy, or cost-effectiveness advantages. Additional risks include the possibility that the patent application may not result in a granted patent, challenges in advancing the collaboration between NeuroThera and Clearmind, regulatory approval hurdles, and general business and economic uncertainties. Further information about these risks is available in the Company's public filings on https://www.sedarplus.ca.
The development represents a significant step in addressing the global burden of depression through innovative pharmaceutical approaches. As major depressive disorder continues to affect millions worldwide, the pursuit of novel treatment options with potentially improved safety profiles and accessibility could have substantial implications for mental healthcare delivery and patient outcomes across multiple healthcare systems.
